Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial

OBJECTIVE: The BEACON CRC randomised controlled trial (NCT02928224) in BRAF-mutant metastatic colorectal cancer (mCRC) patients showed improved overall survival for the combination treatment of encorafenib (BRAF inhibitor) with cetuximab (EGFR inhibitor) compared with cetuximab with chemotherapy (FO...

Descripción completa

Detalles Bibliográficos
Autores principales: Trouiller, Jean-Baptiste, Macabeo, Bérengère, Poll, Andrew, Howard, Dan, Buckland, Andy, Sivignon, Marine, Clay, Emilie, Malka, David, Samalin, Emmanuelle, Toumi, Mondher, Laramée, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Health Economics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680156/
https://www.ncbi.nlm.nih.gov/pubmed/36410812
http://dx.doi.org/10.1136/bmjopen-2022-063700

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9680156/
https://www.ncbi.nlm.nih.gov/pubmed/36410812
http://dx.doi.org/10.1136/bmjopen-2022-063700

Ejemplares similares